摘要 |
The present invention is based on the discovery that in patients infected with Genotype 1 of the Hepatitis C virus (HCV-1) or Genotype 4 HCV (HCV-4) that undergo Triple Therapy treatment, certain biomarkers can be predictive of a patient achieving sustained virologic response |